Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.72 |
| ▸ | GAK | O14976 | 5/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.66 |
| ▸ | ILK | Q13418 | 2/20 | 0.62 |
| ▸ | PLK4 | O00444 | 1/20 | 0.62 |
| ▸ | CIT | O14578 | 1/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.62 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.62 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.62 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.62 |
| ▸ | BUB1 | O43683 | 1/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.62 |
| ▸ | JAK2 | O60674 | 1/20 | 0.62 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.62 |
| ▸ | STK17B | O94768 | 1/20 | 0.62 |
| ▸ | STK10 | O94804 | 1/20 | 0.62 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13847566 | 0.90 | EGFR (0.62) | EGFRGAKERBB2HDAC1ILK | |
| SCHEMBL20127272 | 0.88 | EGFR (0.57) | EGFRGAKERBB2HDAC1ILK | |
| SCHEMBL29749690 | 0.84 | EGFR (1.00) | EGFRGAKERBB2HDAC1ILK | |
| SCHEMBL13824816 | 0.84 | EGFR (1.00) | EGFRGAKERBB2HDAC1ILK | |
| Hydrochloric Acid SCHEMBL29785616 | 0.83 | EGFR (0.98) | EGFRGAKERBB2HDAC1ILK | |
| SCHEMBL13815419 | 0.81 | EGFR (0.67) | EGFRGAKERBB2HDAC1ILK | |
| Hydrochloric Acid SCHEMBL29785631 | 0.80 | EGFR (0.72) | EGFRGAKERBB2HDAC1ILK | |
| Erlotinib SCHEMBL3667407 | 0.77 | EGFR (1.00) | EGFRGAKERBB2HDAC1ILK | |
| SCHEMBL6070549 | 0.77 | EGFR (0.62) | EGFRGAKERBB2ILKPLK4 | |
| Erlotinib SCHEMBL29351329 | 0.77 | EGFR (1.00) | EGFRGAKERBB2HDAC1ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210100802-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. (US) | 2021-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210100802-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ERBB2, EGFR, ERBB3 | EGFR 2/4885GAK 103/4885ERBB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.